Compare Recursion Pharmaceuticals Inc (RXRX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B), while Schwab US Dividend Equity ETF trades at $33.12 (market cap $108.68B). The key difference: Schwab US Dividend Equity ETF is far larger — about 47× Recursion Pharmaceuticals Inc's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| RXRX | SCHD | |
|---|---|---|
Market Cap | $2.31B | $108.68B |
Volume | 40,478,768 | 21,463,071 |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $35.21 |
52-Week Low | $2.84 | $26.44 |
Typical Hold Time | 22 Days | 62 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.
Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
